OBJECTIVE:To compare the dissolution rates of levofloxacin tablets produced in 4 domestic pharmaceutical manufacturers in order to provide the evidence for its clinical use.METHODS:UV spectrohpotmetry was used to determine the cumulative dissolution rates of these 4 kinds of levofloxacin tablets at different time points,the dissolution parameters of T50,Td,T80,and M were calculated by Weibull formula,then variance analysis was made.RESULTS:The dissolution rates of these 4 kinds of levofloxacin tablets all met the standards recorded in 2000 edition of China Pharmacopoeia,but significant differences were found in parameters of T50,Td,T80,and M(P

OBJECTIVE:To develop a HPLC assay for the determination of 7 kinds of amino acids in amino acid capsules by using online derivation and diode array detector.METHODS:The high performance chromatograph of liquid with the device of automatic derivation was employed as the automatic sampler.The samples were injected in the predefined procedure,and detected with the diode array detector.RESULTS:Good resolution of 7 kinds of amino acids was obtained,and the respective detectable concentration showed a good linear relationship with its peak area.CONCLUSION:The present method is convenient,well reproduced, highly sensitive,and accurate,therefore it can be widely used.

OBJECTIVE:To study the quality standard of compound polysaccharide selenate capsules(CPSC).METHODS:Astragalus and oldenlandia were identified by TLC method and the content of selenium in CPSC was determined by fluo?rospectrophotometry.RESULTS:Linear range was0～0.5?g/ml and average recovery was100.4%,RSD=0.91%(n=5). CONCLUSION:This method is simple and accurate,and can be used for quality control of CPSC.

OBJECTIVE To evaluate the therapeutic efficacy and safety of vonoprazan-based triple therapy in treatment-naive patients with Helicobacter pylori （Hp） infection. METHODS From March 2022 to August 2023， 198 treatment-naive patients with Hp infection treated at the outpatient service of department of gastroenterology in our hospital were assigned to the vonoprazan- based triple therapy group （VAC group， n＝98） and the bismuth-based quadruple therapy group （BQT group， n＝100） using the random number table method. Patients in VAC group were given Vonoprazan fumarate tablets （20 mg） + Amoxicillin capsules （1 g） + Clarithromycin tablets （0.5 g）， all twice daily. Patients in BQT group were given Esomeprazole magnesium enteric-coated tablets （20 mg， twice daily） + Metronidazole tablets （0.4 g， four times daily） + Tetracycline tablets （0.5 g， three times daily） + Bismuth potassium citrate capsules （0.6 g， twice daily）. The treatment course for both groups was 14 days. The Hp eradication rates were compared between the two groups in intention-to-treat （ITT）， modified intention-to-treat （MITT）， and per-protocol （PP） analysis sets， while adverse reaction occurrence and medication compliance of two groups were recorded. RESULTS In the ITT， MITT and PP analyses sets， the Hp eradication rates in VAC group were non-inferior to those in BQT group. The incidences of grades 1-2 nausea， vomiting， and loss of appetite in VAC group were significantly lower than in BQT group， and the proportion of patients with good compliance was significantly higher in VAC group （P＜0.05）. Regardless of whether the body mass index （BMI） ≤25 kg/m2 or ＞25 kg/m2， no statistically significant difference was observed in the Hp eradication rates between the two groups （P＞0.05）. CONCLUSIONS Vonoprazan-based triple therapy is non-inferior to bismuth-based quadruple therapy in the treatment of treatment-naive patients with Hp infection， with higher safety and good patient medication compliance. BMI has no significant impact on the Hp eradication rate.